Anti-tumor necrosis factor therapies for psoriasis

References

• Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch. Dermatol.140, 218–225 (2004).
   PubMed Web of Science ®Google Scholar
• Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor α (TNF-α) blockade in psoriasis and psoriatic arthritis. Clin. Dermatol.21, 392–397 (2003).
   PubMed Web of Science ®Google Scholar
• Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum.36, 159–167 (2006).
   PubMed Web of Science ®Google Scholar
• Lizzul PF, Aphale A, Malaviya R et al. Differential expression of phosphorylated NF-κB/RelA in normal and psoriatic epidermis and downregulation of NF-κB in response to treatment with etanercept. J. Invest. Dermatol.124, 1275–1283 (2005).
   PubMed Web of Science ®Google Scholar
• Enbrel® Package Insert (US FDA – label approved June 2006).
   Google Scholar
• Enbrel® Package Insert (EMEA – Rev. 14, published December 2006).
   Google Scholar
• Remicade® Package Insert (US FDA – label approved October 2006).
   Google Scholar
• Remicade® Package Insert (EMEA – Rev. 13, published November 2006).
   Google Scholar
• Humira® Package Insert (US FDA – label approved February 2007).
   Google Scholar
• Humira® Package Insert (EMEA – Rev. 4, published November 2006).
   Google Scholar
• Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther.301, 418–426 (2002).
   PubMed Web of Science ®Google Scholar
• Shen C, Assche GV, Colpaert S et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther.21, 251–258 (2005).
   PubMed Web of Science ®Google Scholar
• Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin. Arthritis Rheum.34(5 Suppl. 1), 12–18 (2005).
   PubMed Web of Science ®Google Scholar
• Rojas JR, Taylor RP, Cunningham MR et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J. Pharmacol. Exp. Ther.313, 578–585 (2005).
   PubMed Web of Science ®Google Scholar
• Ogilvie AL, Luftl M, Antoni C, Schuler G, Kalden JR, Lorenz HM. Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-α. Int. J. Immunopathol. Pharmacol.19, 271–278 (2006).
   PubMed Web of Science ®Google Scholar
• Cordiali-Fei P, Trento E, D’Agosto G et al. Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α. J. Autoimmune Dis.3, 5 (2006).
   PubMedGoogle Scholar
• Markham T, Mullan R, Golden-Mason L et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J. Am. Acad. Dermatol.546, 1003–1012 (2006).
   Google Scholar
• Goedkoop AY, Kraan MC, Picavet DI et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res. Ther.6, R326–R334 (2004).
   PubMed Web of Science ®Google Scholar
• Goedkoop AY, Kraan MC, Teunissen MB et al. Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rheum. Dis.63, 769–773 (2004).
   PubMed Web of Science ®Google Scholar
• Malaviya R, Sun Y, Tan JK, Magliocco M, Gottlieb AB. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis. J. Drugs Dermatol.5, 890–893 (2006).
   PubMedGoogle Scholar
• Markham T, Mathews C, Rogers S et al. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. Br. J. Dermatol.155, 1191–1196 (2006).
   PubMedGoogle Scholar
• Kruger-Krasagakis S, Galanopoulos VK, Giannikaki L, Stefanidou M, Tosca AD. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br. J. Dermatol.154, 460–466 (2006).
   PubMed Web of Science ®Google Scholar
• Bovenschen HJ, Van De Kerkhof PC, Gerritsen WJ, Seyger MM. The role of lesional T cells in recalcitrant psoriasis during infliximab therapy. Eur. J. Dermatol.15, 454–458 (2005).
   Google Scholar
• Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol.175, 2721–2729 (2005).
   PubMed Web of Science ®Google Scholar
• Malaviya R, Sun Y, Tan J et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J. Am. Acad. Dermatol.55, 590–597 (2006).
   PubMedGoogle Scholar
• Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ. The tumour necrosis factor-α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br. J. Dermatol.153, 945–953 (2005).
   PubMed Web of Science ®Google Scholar
• Riccieri V, Spadaro A, Taccari E et al. Analisi immunoistochimica dell’espressione delle principali molecole di adesione e dei fattori di necrosi tumorale a livello della membrana sinoviale nell'artrite psoriasica. Reumatismo55, 164–170 (2003).
   PubMedGoogle Scholar
• Hashigucci K, Yokoyama M, Niizeki H et al. Polymorphism in the tumor necrosis factor B gene is associated with palmoplantar pustulosis. Tissue Antigens54, 288–290 (1999).
   Google Scholar
• Kim TG, Pyo CW, Hur SS et al. Polymorphisms of tumor necrosis factor (TNF) α and β genes in Korean patients with psoriasis. Arch. Dermatol. Res.295, 8–13 (2003).
   PubMedGoogle Scholar
• Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol.139, 1627–1632 (2003).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med.349, 2014–2022 (2003).
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M et al. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol.152, 1304–1312 (2005).
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet357, 1842–1847 (2001).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol.51, 534–542 (2004).
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet366, 1367–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Mössner R, Reich K. Infliximab in the treatment of psoriasis. Expert Rev. Dermatol.1(4), 515–526 (2006).
   Google Scholar
• Gratch N, Weinberg JM, Alexis AF. Etanercept: a tumor necrosis factor inhibitor for psoriasis and psoriatic arthritis. Expert Rev. Dermatol.1(4), 527–534 (2006).
   Google Scholar
• Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol.55, 598–606 (2006).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.52, 3279–3289 (2005).
   PubMed Web of Science ®Google Scholar
• Gladman DD. Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review. Drugs65, 1223–1238 (2005).
   Google Scholar
• Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis.66(2), 163–168 (2007).
   PubMed Web of Science ®Google Scholar
• Elewski B, Leonardi C, Gottlieb AB et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br. J. Dermatol.156, 138–142 (2007).
   PubMedGoogle Scholar
• Cassano N, Loconsole F, Galluccio A et al. Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (POWER study). Int. J. Immunopathol. Pharmacol.19, 225–229 (2006).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Gottlieb AB, Leonardi CL et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J. Dermatol. Treat.17, 9–17 (2006).
   PubMed Web of Science ®Google Scholar
• Moore A, Gordon KB, Kang S et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J. Am. Acad. Dermatol.56(4), 598–603 (2007).
   PubMed Web of Science ®Google Scholar
• Leonardi C, Boh E, Langley R, Krueger G. Assessment of response variability in patients treated with step-down etanercept therapy over 48 weeks. J. Am. Acad. Dermatol.54(Suppl. 3), 2861 (2006).
   Google Scholar
• Tyring S, Poulin Y, Langley R, Gordon K. A 96-week Phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis. J. Am. Acad. Dermatol.54(Suppl. 3), 39 (2006).
   Google Scholar
• de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD. Initial experience with routine administration of etanercept in psoriasis. Br. J. Dermatol.155, 808–814 (2006).
   PubMedGoogle Scholar
• Strober B, Gottlieb AB, Johnson R, Leonardi C, Papp K. Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. J. Am. Acad. Dermatol.54(Suppl. 3), 2890 (2006).
   Google Scholar
• Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J. Am. Acad. Dermatol.48, 829–835 (2003).
   PubMed Web of Science ®Google Scholar
• Cassano N, Loconsole F, Amoruso A et al. Infliximab monotherapy for refractory psoriasis: preliminary results. Int. J. Immunopathol. Pharmacol.17, 373–380 (2004).
   Google Scholar
• Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease – seven years on. Aliment. Pharmacol. Ther.23, 451–463 (2006).
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol.56, 31.e1–31e.15 (2007).
   PubMed Web of Science ®Google Scholar
• Kalb RE, Gurske J. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J. Am. Acad. Dermatol.53, 616–622 (2005).
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum.54, 3782–3789 (2006).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Elewski B, Papp K, Wang A, Zitnik R, Jahreis A. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J. Am. Acad. Dermatol.54(3 Suppl. 2), S112–S119 (2006).
   PubMed Web of Science ®Google Scholar
• Papp K, Griffiths CEM, Li S, Guzzo C. Achievement of response after initial partial or lack of response to infliximab therapy in psoriasis patients: data from EXPRESS and EXPRESS II. J. Am. Acad. Dermatol.54(Suppl. 3), 2854 (2006).
   Google Scholar
• Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin. Cutan. Med. Surg.24, 37–45 (2005).
   PubMed Web of Science ®Google Scholar
• Jacob SE, Sergay A, Kerdel FA. Etanercept and psoriasis, from clinical studies to real life. Int. J. Dermatol.44, 688–691 (2005).
   Google Scholar
• Yamauchi PS, Lowe NJ. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. J. Am. Acad. Dermatol.54(3 Suppl. 2), S135–S138 (2006).
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res. Ther.8, R29 (2006).
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum.56, 13–20 (2006).
   Google Scholar
• Cohen JD, Bournerias I, Buffard V et al. Psoriasis induced by tumor necrosis factor-α antagonist therapy: a case series. J. Rheumatol.34(2), 380–385 (2007).
   PubMed Web of Science ®Google Scholar
• Goiriz R, Dauden E, Perez-Gala S, Guhl G, Garcia-Diez A. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin. Exp. Dermatol.32(2), 176–179 (2006).
   PubMedGoogle Scholar
• Cassano N, Coviello C, Loconsole F, Miracapillo A, Vena GA. Psoriasis exacerbation after a flu-like syndrome during anti-TNF-α therapy. Eur. J. Dermatol.16, 316–317 (2006).
   PubMedGoogle Scholar
• Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO. Generalised pustular psoriasis induced by cyclosporine A withdrawal responding to the tumour necrosis factor α inhibitor etanercept. Dermatology205, 213–216 (2002).
   PubMed Web of Science ®Google Scholar
• Trent JT, Kerdel FA. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J. Cutan. Med. Surg.8, 224–228 (2004).
   PubMed Web of Science ®Google Scholar
• Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J. Dermatol. Treat.16, 350–352 (2005).
   PubMed Web of Science ®Google Scholar
• Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept. Br. J. Dermatol.155, 156–159 (2006).
   PubMed Web of Science ®Google Scholar
• Weisenseel P, Prinz JC. Sequential use of infliximab and etanercept in generalized pustular psoriasis. Cutis78, 197–199 (2006).
   PubMedGoogle Scholar
• Bonish B, Rashid RM, Swan J. Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing? J. Drugs Dermatol.5, 903–904 (2006).
   PubMedGoogle Scholar
• Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr. Dermatol.21, 87–88 (2004).
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Costanzo A, Mazzotta A, Gramiccia T, Soda R, Chimenti S. Etanercept for the treatment of severe childhood psoriasis. Br. J. Dermatol.154, 181–183 (2006).
   PubMed Web of Science ®Google Scholar
• Desay SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract. Res. Clin. Rheumatol.20, 7757–7790 (2006).
   Web of Science ®Google Scholar
• Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum.52, 1766–1772 (2005).
   PubMed Web of Science ®Google Scholar
• Orenstein R. Infections related to TNF-α inhibitors. Expert Rev. Dermatol.1(5), 737–749 (2006).
   Google Scholar
• Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a Phase 2 randomized, double-blind, placebo-controlled study. J. Hepatol.42, 315–322 (2005).
   PubMed Web of Science ®Google Scholar
• Ting PT, Koo JY. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int. J. Dermatol.45, 689–692 (2006).
   PubMed Web of Science ®Google Scholar
• Geborek P, Bladstrom A, Turesson C et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis.64, 699–703 (2005).
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis.64, 1414–1420 (2005).
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J. Invest. Dermatol.126, 2194–2201 (2006).
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med.138, 807–811 (2003).
   PubMed Web of Science ®Google Scholar
• Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis190, 1–9 (2007).
   PubMed Web of Science ®Google Scholar
• Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin. Exp. Rheumatol.22(5 Suppl. 35), S134–S140 (2004).
   Google Scholar
• De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus15, 762–767 (2006).
   PubMed Web of Science ®Google Scholar
• Katz JA, Antoni CE, Keenan GF et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease or rheumatoid arthritis. Am. J. Gastroenterol.99, 2385–2392 (2004).
   PubMed Web of Science ®Google Scholar
• Koksvik HS, Magnussen AS, Skomsvoll JF. One year follow-up of etanercept exposed pregnancies. Ann. Rheum. Dis.64(Suppl. 3), 449 (2005).
   Google Scholar
• Vena GA, Cassano N. Emerging drugs for psoriasis. Expert. Opin. Emerg. Drugs11, 567–596 (2006).
   PubMedGoogle Scholar
• Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br. J. Dermatol.153, 486–497 (2005).
   PubMed Web of Science ®Google Scholar